Galectin gets fast-track designation for fatty liver disease drug


The FDA grants fast-track designation to Galectin Therapeutics' (GALT) GR-MD-O2 treatment for treating non-alcoholic steatohepatitis (NASH) with hepatic fibrosis, commonly known as fatty liver disease with advanced fibrosis. It's a condition associated with obesity and affects 9-15M people in the U.S., including children.

GR-MD-O2 is in Phase I trials

"Our preclinical data has shown that GR-MD-02 has robust treatment effects in reversing fibrosis and cirrhosis," says CEO Peter Traber. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs